K-RAS and N-RAS mutations in testicular germ cell tumors

Basit Öğe Kaydı
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridKöstek, Osman/0000-0002-1901-5603;
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidKöstek, Osman/AAA-3604-2019
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.contributor.authorHacioglu, Bekir Muhammet
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorErdogan, Bulent
dc.contributor.authorCinkaya, Ahmet
dc.contributor.authorTastekin, Ebru
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorTurkmen, Esma
dc.date.accessioned2024-06-12T11:16:10Z
dc.date.available2024-06-12T11:16:10Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractTesticular cancer is a relatively rare tumor type, accounting for approximately 1% of all cancers in men. However, among men aged between 15 and 40 years, testicular cancer is the most commonly diagnosed malignancy. Testicular germ cell tumors (TGCTs) are classified as seminoma and non-seminoma. The RAS oncogene controls several cellular functions, including cell proliferation, apoptosis, migration, and differentiation. Thus, RAS signaling is important for normal germ cell development. Mutations of the Kirsten RAS (K-RAS) gene are present in over 20% of all cancers. RAS gene mutations have also been reported in TGCTs. We investigated K-RAS and N-RAS mutations in seminoma and non-seminoma TGCT patients. A total of 24 (55%) pure seminoma cases and 19 (45%) non-seminoma cases were included in the study. K-RAS and N-RAS analyses were performed in our molecular pathology laboratory, using K-RAS and N-RAS Pyro Kit 24 V1 (Qiagen). In total, a RAS mutation was present in 12 patients (27%): 7 seminoma (29%) and 5 non-seminoma cases (26%) [p = 0.55]. AK-RAS mutation was present in 4 pure seminoma tumors (16%) and 3 non-seminoma tumors (15%) [p = 0.63], and an N-RAS mutation was observed in 4 seminoma tumors (16%) and 3 non-seminoma tumors (15%) [p = 0.63]. Both, K-RAS and N-RAS mutations were present in two patients: One with seminoma tumor and the other with non-seminoma tumor. To date, no approved targeted therapy is available for the treatment of TGCTs. The analysis of K-RAS and N-RAS mutations in these tumors may provide more treatment options, especially in platinum-resistant tumors.en_US
dc.identifier.doi10.17305/bjbms.2017.1764
dc.identifier.endpage163en_US
dc.identifier.issn1512-8601
dc.identifier.issn1840-4812
dc.identifier.issue2en_US
dc.identifier.pmid28426398en_US
dc.identifier.scopus2-s2.0-85019753693en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage159en_US
dc.identifier.urihttps://doi.org/10.17305/bjbms.2017.1764
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24201
dc.identifier.volume17en_US
dc.identifier.wosWOS:000405628800012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevoen_US
dc.relation.ispartofBosnian Journal Of Basic Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTesticular Germ Cell Tumorsen_US
dc.subjectSeminomaen_US
dc.subjectNon-Seminomaen_US
dc.subjectK-RAS Mutationen_US
dc.subjectN-RAS Mutationen_US
dc.subjectTGCTen_US
dc.subjectMetastatic Colorectal-Canceren_US
dc.subjectPolymerase Chain-Reactionen_US
dc.subjectSomatic Mutationsen_US
dc.subjectBrafen_US
dc.subjectBiologyen_US
dc.subjectPik3caen_US
dc.subjectKiten_US
dc.titleK-RAS and N-RAS mutations in testicular germ cell tumorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu